Thus, loss of KRIT1, CCM2 or CCM3 hyperactivates RhoA–ROCK signalling, and RhoA/ROCK inhibitors may be a viable pharmacologic treatment option for CCM disease. The gene discussed is RHOA; the disease is cerebral cavernous malformation.